• GlaxoSmithKline plc, of London, said it plans to invest more than £500 million (US$790.9 million) in its UK manufacturing sites to increase production of key active ingredients for its pharmaceutical products and vaccines. The company said it will build a £350 million biopharmaceutical manufacturing facility at Ulverston, Cumbria, and invest more than £100 million across two manufacturing sites in Scotland.